Focus
View

Revolution Medicines, Inc.

RVMD · FY2025

MIXED

CEO Package

$14.7M

Pay Ratio

—

Mark A. Goldsmith

Pay and TSR both rose, but not in lockstep

Amgen Inc.

AMGN · FY2024

MISALIGNED

CEO Package

$24.4M

Pay Ratio

—

Robert A. Bradway

Pay rose +7.4% while TSR fell -19.2 pts

GILEAD SCIENCES, INC.

GILD · FY2025

ALIGNED

CEO Package

$28.4M

Pay Ratio

—

Daniel P. O’Day

Returns outran pay growth by -1.2 pts

CEOTotal Compensation — All Companies

RVMD$14.7MAMGN$24.4MGILD$28.4M

All values are grant-date fair value as reported in proxy statements.

Key Differences

The fastest way to read this comparison before dropping into the tables.

GILD carries the largest package at $28.4M, about 1.9x RVMD.
AMGN reads misaligned, while GILD looks aligned.

Pay Component Breakdown

Latest CEO package mix by company. This stays on the CEO package even if the chart above is showing Top 5 pay.

RVMD

Mark A. Goldsmith

$14.7M

base salary6%
stock awards27%
option awards61%
non-equity incentive compensation6%
other compensation0%

AMGN

Robert A. Bradway

$24.4M

base salary8%
stock awards52%
option awards22%
non-equity incentive compensation16%
other compensation3%

GILD

Daniel P. O’Day

$28.4M

base salary6%
stock awards54%
option awards16%
non-equity incentive compensation17%
other compensation7%

Quick Comparison

CompanyCEOLatest YearTotal Comp
Revolution Medicines, Inc.(RVMD)Mark A. Goldsmith2025$14.7M
Amgen Inc.(AMGN)N/A2025N/A
GILEAD SCIENCES, INC.(GILD)Daniel P. O’Day2025$28.4M

Note: All compensation values shown are grant-date fair value as reported in proxy statements. Direct comparisons should account for differences in company size, industry, and compensation structure.

Want to know when these numbers change?

We’ll email you when these companies file a new proxy — so you can see how CEO pay, equity awards, and ratios shift before the next headline.